Clinical Trials Logo

Recurrent Lymphoma clinical trials

View clinical trials related to Recurrent Lymphoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05663502 Recruiting - Lymphoma Clinical Trials

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

Start date: May 10, 2023
Phase:
Study type: Observational

This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may help doctors to learn how are biologic or genetic factors related to HIV and cancers that occur commonly in people living with HIV.

NCT ID: NCT04870944 Recruiting - Clinical trials for Refractory Malignant Solid Neoplasm

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Start date: January 28, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.

NCT ID: NCT03418038 Recruiting - Clinical trials for Chronic Myelomonocytic Leukemia

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Start date: March 23, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may kill more cancer cells.

NCT ID: NCT01790152 Recruiting - Osteosarcoma Clinical Trials

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Start date: March 5, 2014
Phase:
Study type: Observational

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.